NASDAQ:ALKS Alkermes (ALKS) Stock Price, News & Analysis → AI “wealth window” is closing soon! (From Paradigm Press) (Ad) Free ALKS Stock Alerts $23.76 -0.25 (-1.04%) (As of 04/18/2024 ET) Add Compare Share Share Today's Range$23.62▼$24.1450-Day Range$23.77▼$32.5652-Week Range$22.01▼$33.71Volume1.80 million shsAverage Volume1.91 million shsMarket Capitalization$4.02 billionP/E Ratio11.48Dividend YieldN/APrice Target$35.25 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Alkermes alerts: Email Address Alkermes MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside48.4% Upside$35.25 Price TargetShort InterestBearish8.48% of Shares Sold ShortDividend StrengthN/ASustainability-1.17Upright™ Environmental ScoreNews Sentiment0.42Based on 23 Articles This WeekInsider TradingSelling Shares$292,718 Sold Last QuarterProj. Earnings Growth-6.28%From $2.23 to $2.09 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.24 out of 5 starsMedical Sector131st out of 919 stocksPharmaceutical Preparations Industry42nd out of 406 stocks 3.3 Analyst's Opinion Consensus RatingAlkermes has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 6 buy ratings, 3 hold ratings, and 1 sell rating.Amount of Analyst CoverageAlkermes has only been the subject of 4 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted8.48% of the outstanding shares of Alkermes have been sold short.Short Interest Ratio / Days to CoverAlkermes has a short interest ratio ("days to cover") of 7.5.Change versus previous monthShort interest in Alkermes has recently increased by 1.85%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAlkermes does not currently pay a dividend.Dividend GrowthAlkermes does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAlkermes has received a 60.90% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for physical health", "Antipsychotics", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Alkermes is -1.17. Previous Next 1.9 News and Social Media Coverage News SentimentAlkermes has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 23 news articles for Alkermes this week, compared to 6 articles on an average week.Search InterestOnly 1 people have searched for ALKS on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Alkermes to their MarketBeat watchlist in the last 30 days. This is a decrease of -17% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Alkermes insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $292,718.00 in company stock.Percentage Held by InsidersOnly 4.76% of the stock of Alkermes is held by insiders.Percentage Held by Institutions95.21% of the stock of Alkermes is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 2.5 Earnings and Valuation Earnings GrowthEarnings for Alkermes are expected to decrease by -6.28% in the coming year, from $2.23 to $2.09 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Alkermes is 11.48, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 142.12.Price to Earnings Ratio vs. SectorThe P/E ratio of Alkermes is 11.48, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 230.61.Price to Earnings Growth RatioAlkermes has a PEG Ratio of 0.66. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioAlkermes has a P/B Ratio of 3.30. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Darwin2024's Must-Have Guide: Master Crypto Investment TodayThe cryptocurrency revolution is here with Bitcoin soaring past the $70,000 milestone—a clear indicator of the booming digital currency market. Are you prepared to navigate these exciting yet complex waters? Introducing "Navigating the Future: A Comprehensive Guide to Cryptocurrency Investments in 2024." This free digital guide is your essential resource for understanding and capitalizing on cryptocurrency investments, tailored for both newcomers and seasoned investors. (**By clicking the link you are subscribing to The Conservative Investor Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)Click here to download your crypto report About Alkermes Stock (NASDAQ:ALKS)Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.Read More ALKS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALKS Stock News HeadlinesMarch 19, 2024 | insidertrades.comAlkermes plc (NASDAQ:ALKS) SVP Sells $292,717.70 in StockApril 17, 2024 | prnewswire.comAlkermes to Report First Quarter Financial Results on May 1, 2024April 18, 2024 | Darwin (Ad)Your Next Portfolio Star: Revealing 2024's Top Stock Pick We're thrilled to offer you an exclusive look at the #1 Buy & Hold Stock of 2024. This isn't just any report. It's the culmination of rigorous analysis, expert insights, and cutting-edge financial strategies, distilled into a compelling narrative that charts the course of what we believe to be the year's most promising investment. (**By clicking the link you are subscribing to The Wealth Creation Investing Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)April 17, 2024 | finance.yahoo.comAlkermes (ALKS) Earnings Expected to Grow: What to Know Ahead of Q1 ReleaseApril 13, 2024 | americanbankingnews.comAlkermes plc Forecasted to Post Q3 2025 Earnings of $0.52 Per Share (NASDAQ:ALKS)April 13, 2024 | americanbankingnews.comFY2024 EPS Estimates for Alkermes plc (NASDAQ:ALKS) Reduced by AnalystApril 12, 2024 | markets.businessinsider.comHold Rating on Alkermes Amid Promising ALKS 2680 Data and Regulatory ChallengesApril 12, 2024 | americanbankingnews.comFY2025 EPS Estimates for Alkermes plc Raised by Zacks Research (NASDAQ:ALKS)April 18, 2024 | Darwin (Ad)Your Next Portfolio Star: Revealing 2024's Top Stock Pick We're thrilled to offer you an exclusive look at the #1 Buy & Hold Stock of 2024. This isn't just any report. It's the culmination of rigorous analysis, expert insights, and cutting-edge financial strategies, distilled into a compelling narrative that charts the course of what we believe to be the year's most promising investment. (**By clicking the link you are subscribing to The Wealth Creation Investing Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy.)April 12, 2024 | americanbankingnews.comFY2027 Earnings Forecast for Alkermes plc Issued By Leerink Partnrs (NASDAQ:ALKS)April 11, 2024 | investing.comJefferies raises Alkermes stock target on positive OX2 dataApril 11, 2024 | americanbankingnews.comAlkermes (NASDAQ:ALKS) Shares Gap Up After Analyst UpgradeApril 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Alkermes on Promising ALKS 2680 Clinical Trial Results and Growth PotentialApril 10, 2024 | americanbankingnews.comAlkermes (NASDAQ:ALKS) Given New $50.00 Price Target at Jefferies Financial GroupApril 9, 2024 | markets.businessinsider.comBreaking Down Alkermes: 5 Analysts Share Their ViewsApril 9, 2024 | msn.comAlkermes posts early-stage win for sleeping disorder therapy (update)April 9, 2024 | seekingalpha.comAlkermes: Waking Up Narcolepsy Treatment With Promising Trial DataApril 9, 2024 | msn.comAlkermes succeeds in early-stage trial for sleeping disorder therapyApril 9, 2024 | seekingalpha.comAlkermes plc: Collecting The Fruits Of The 2023 SpinoffApril 9, 2024 | prnewswire.comAlkermes Announces Positive Topline Results From Phase 1b Study of ALKS 2680 Demonstrating Improved Wakefulness in Patients With Narcolepsy Type 2 and Idiopathic HypersomniaApril 8, 2024 | prnewswire.comAlkermes Presents Analyses From Long-Term Safety Study of LYBALVI® (olanzapine and samidorphan) at 2024 Congress of the Schizophrenia International Research SocietyMarch 29, 2024 | finance.yahoo.comInvestors in Alkermes (NASDAQ:ALKS) have seen favorable returns of 44% over the past three yearsMarch 28, 2024 | nasdaq.comNoteworthy Tuesday Option Activity: ALKS, DKNG, VRTMarch 20, 2024 | investing.comAlkermes exec sells over $290k in company sharesMarch 19, 2024 | msn.comBaird starts Alkermes at outperform, citing revenue streamMarch 19, 2024 | markets.businessinsider.comThe Analyst Verdict: Alkermes In The Eyes Of 4 ExpertsMarch 18, 2024 | finance.yahoo.comInsider Sell: SVP, Chief Commercial Officer Christian Nichols Sells Shares of Alkermes PLC (ALKS)See More Headlines Receive ALKS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alkermes and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/15/2024Today4/18/2024Next Earnings (Confirmed)5/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:ALKS CUSIPG0176710 CIK1520262 Webwww.alkermes.com Phone(531) 772-8000Fax781-890-0524Employees2,100Year Founded1987Price Target and Rating Average Stock Price Target$35.25 High Stock Price Target$50.00 Low Stock Price Target$25.00 Potential Upside/Downside+48.4%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)$2.07 Trailing P/E Ratio11.48 Forward P/E Ratio10.65 P/E Growth0.66Net Income$355.76 million Net Margins21.39% Pretax Margin25.34% Return on Equity16.10% Return on Assets9.15% Debt Debt-to-Equity Ratio0.24 Current Ratio2.86 Quick Ratio2.50 Sales & Book Value Annual Sales$1.66 billion Price / Sales2.42 Cash Flow$2.27 per share Price / Cash Flow10.47 Book Value$7.21 per share Price / Book3.30Miscellaneous Outstanding Shares169,180,000Free Float161,131,000Market Cap$4.02 billion OptionableOptionable Beta0.55 Social Links 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesMr. Richard F. Pops (Age 62)Chairman & CEO Comp: $2.3MMr. Blair C. Jackson (Age 51)Interim Principal Financial Officer, Executive VP & COO Comp: $1.05MMr. David Joseph Gaffin (Age 52)Executive VP, Chief Legal Officer, Chief Compliance Officer & Secretary Comp: $1.08MMr. Iain Michael Brown (Age 55)Senior VP & CFO (Leave of Absence) Comp: $867.75kDr. Craig C. Hopkinson M.D. (Age 56)Executive VP of Research & Development and Chief Medical Officer Comp: $1.12MDr. Floyd E. Bloom M.D. (Age 87)Founder Comp: $57.73kMr. Samuel J. Parisi (Age 49)Interim Principal Accounting Officer & VP of Finance Mr. Thomas HarveyChief Information Officer & Senior VP of ITMs. Sandra CoombsSenior Vice President of Corporate Affairs & Investor RelationsMr. Michael J. Landine (Age 70)Senior VP of Corporate Development & Chief Risk Officer Comp: $750.46kMore ExecutivesKey CompetitorsMadrigal PharmaceuticalsNASDAQ:MDGLEidos TherapeuticsNASDAQ:EIDXAmicus TherapeuticsNASDAQ:FOLDIonis PharmaceuticalsNASDAQ:IONSGeronNASDAQ:GERNView All CompetitorsInsiders & InstitutionsAllspring Global Investments Holdings LLCSold 256,788 shares on 4/18/2024Ownership: 0.071%Diversified Trust CoSold 3,913 shares on 4/18/2024Ownership: 0.020%AlphaMark Advisors LLCBought 10,976 shares on 4/18/2024Ownership: 0.006%Guidance Capital Inc.Bought 15,826 shares on 4/17/2024Ownership: 0.009%CWM LLCBought 733 shares on 4/5/2024Ownership: 0.002%View All Insider TransactionsView All Institutional Transactions ALKS Stock Analysis - Frequently Asked Questions Should I buy or sell Alkermes stock right now? 10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alkermes in the last twelve months. There are currently 1 sell rating, 3 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" ALKS shares. View ALKS analyst ratings or view top-rated stocks. What is Alkermes' stock price target for 2024? 10 equities research analysts have issued twelve-month target prices for Alkermes' shares. Their ALKS share price targets range from $25.00 to $50.00. On average, they expect the company's stock price to reach $35.25 in the next twelve months. This suggests a possible upside of 48.4% from the stock's current price. View analysts price targets for ALKS or view top-rated stocks among Wall Street analysts. How have ALKS shares performed in 2024? Alkermes' stock was trading at $27.74 on January 1st, 2024. Since then, ALKS shares have decreased by 14.3% and is now trading at $23.76. View the best growth stocks for 2024 here. When is Alkermes' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 1st 2024. View our ALKS earnings forecast. How were Alkermes' earnings last quarter? Alkermes plc (NASDAQ:ALKS) issued its earnings results on Thursday, February, 15th. The company reported $0.22 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.51 by $0.29. The company had revenue of $377.50 million for the quarter, compared to analyst estimates of $362.78 million. Alkermes had a trailing twelve-month return on equity of 16.10% and a net margin of 21.39%. The firm's revenue was up 23.9% on a year-over-year basis. During the same period last year, the firm posted ($0.02) EPS. What ETFs hold Alkermes' stock? ETFs with the largest weight of Alkermes (NASDAQ:ALKS) stock in their portfolio include Subversive Mental Health ETF (SANE), AdvisorShares Psychedelics ETF (PSIL), iShares Neuroscience and Healthcare ETF (IBRN), Invesco S&P SmallCap Health Care ETF (PSCH), Horizon Kinetics Medical ETF (MEDX), First Trust NYSE Arca Biotechnology Index Fund (FBT), ALPS Medical Breakthroughs ETF (SBIO) and Pacer US Small Cap Cash Cows 100 ETF (CALF). How will Alkermes' stock buyback program work? Alkermes declared that its Board of Directors has authorized a share buyback program on Thursday, February 15th 2024, which authorizes the company to buyback $400,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization authorizes the company to repurchase up to 8.2% of its shares through open market purchases. Shares buyback programs are generally an indication that the company's board of directors believes its stock is undervalued. What guidance has Alkermes issued on next quarter's earnings? Alkermes updated its FY 2024 earnings guidance on Friday, February, 16th. The company provided earnings per share (EPS) guidance of 2.800-2.800 for the period, compared to the consensus earnings per share estimate of 2.520. The company issued revenue guidance of $1.5 billion-$1.6 billion, compared to the consensus revenue estimate of $1.5 billion. What is Richard F. Pops' approval rating as Alkermes' CEO? 119 employees have rated Alkermes Chief Executive Officer Richard F. Pops on Glassdoor.com. Richard F. Pops has an approval rating of 84% among the company's employees. What other stocks do shareholders of Alkermes own? Based on aggregate information from My MarketBeat watchlists, some companies that other Alkermes investors own include Gilead Sciences (GILD), Netflix (NFLX), Pfizer (PFE), NVIDIA (NVDA), AbbVie (ABBV), Starbucks (SBUX), Intel (INTC), Johnson & Johnson (JNJ) and Tesla (TSLA). Who are Alkermes' major shareholders? Alkermes' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.09%), Allspring Global Investments Holdings LLC (0.07%), Diversified Trust Co (0.02%), Guidance Capital Inc. (0.01%), AlphaMark Advisors LLC (0.01%) and CWM LLC (0.00%). Insiders that own company stock include Blair Curtis Jackson, Cato T Laurencin, Christian Todd Nichols, Craig C Hopkinson, Craig C Hopkinson, David Joseph Gaffin, David W Anstice, Emily Peterson Alva, Iain Michael Brown, Michael J Landine, Nancy Wysenski, Richard F Pops, Shane Cooke and Wendy L Dixon. View institutional ownership trends. How do I buy shares of Alkermes? Shares of ALKS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Does Alkermes have any subsidiaries? The following companies are subsidiares of Alkermes: Rodin Therapeutics.Read More This page (NASDAQ:ALKS) was last updated on 4/18/2024 by MarketBeat.com Staff From Our Partners[Urgent!] Generational Wealth GameplanCrypto 101 MediaThe “Perfect Storm” for GoldGold Safe ExchangeBiden’s $374B Giveaway Into This SectorDTIForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsYour Money is Not SafeAmerican AlternativeThe Next Nvidia?InvestorPlaceHow Biden has already won 2024Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alkermes plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.